UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 6, 2024 (May 31, 2024)

 

ZIVO BIOSCIENCE, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Nevada

 

000-30415

 

87-0699977

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

21 East Long Lake Road, Suite 100,

Bloomfield Hills, Michigan

 

48304

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (248) 452-9866

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ZIVO

 

OTCQB

Warrants to purchase shares of Common

Stock, par value $0.001 per share

 

ZIVOW

 

OTC Pink

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Explanatory Note

 

This Amendment No. 1 on Form 8-K/A (this “Form 8-K/A”) is an amendment to the Current Report on Form 8-K of Zivo Bioscience, Inc., dated May 31, 2024 (the “Original Form 8-K”).  This Form 8-K/A is being filed to correct a typographical error in the date cited in the third sentence of Item 1.01 under the subsection titled Stock Award in Lieu of Unpaid Directors’ Fees of the Original Form 8-K, which is corrected by this filing to be “December 29, 2023”.  This Form 8-K/A amends and restates in its entirety Item 1.01 under the subsection titled Stock Award in Lieu of Unpaid Directors’ Fees of the Original Form 8-K.  Other than the correction to that date, the remainder of the Original Form 8-K remains unchanged.

 

Item 1.01 Entry into a Material Definitive Agreement

 

Stock Award in Lieu of Unpaid Directors’ Fees

 

On May 31, 2024 the Board approved a Stock in Lieu of Unpaid Director's program fees that would allow for the granting of a total of 261,619 shares of stock to the non-employee Board members common in lieu of unpaid non-employee director service fees earned during the calendar year ending December 31, 2023.  In aggregate the Company owed the three non-employee board members $172,670 in fees; Alison Cornell was due $62,789, Nola Masterson was due $56,062, and Chris Maggiore was due $53,819.  These unpaid amounts were grossed up for taxes at an assumed tax rate of 45% and the number of shares was determined based on the Company’s closing stock price on December 29, 2023 of $1.20 per share.  On June 5, 2024, all the non-employee directors accepted the following grants in lieu of the unpaid cash service fees:

 

Non-employee Board Member

Shares Awarded

Alison Cornell

95,134

Chris Maggiore

81,544

Nola Masterson

84,941

 

The value of the shares granted to the non-employee directors pursuant to this exchange of stock in lieu of unpaid cash fees were exempted from the annual limitation of awards to non-employee directors set forth in the Director Equity Plan.  These shares awards will be issued under the Director Equity Plan and will be subject to provisions thereof.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ZIVO BIOSCIENCE, INC.

 

 

 

By:

/s/ Keith Marchiando

 

 

Keith Marchiando

 

 

Chief Financial Officer

 

 

Date: June 7, 2024

 

 

3

  

v3.24.1.1.u2
Cover
Jun. 06, 2024
Cover [Abstract]  
Entity Registrant Name ZIVO BIOSCIENCE, INC.
Entity Central Index Key 0001101026
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 on Form 8-K/A (this “Form 8-K/A”) is an amendment to the Current Report on Form 8-K of Zivo Bioscience, Inc., dated May 31, 2024 (the “Original Form 8-K”). This Form 8-K/A is being filed to correct a typographical error in the date cited in the third sentence of Item 1.01 under the subsection titled Stock Award in Lieu of Unpaid Directors’ Fees of the Original Form 8-K, which is corrected by this filing to be “December 29, 2023”. This Form 8-K/A amends and restates in its entirety Item 1.01 under the subsection titled Stock Award in Lieu of Unpaid Directors’ Fees of the Original Form 8-K. Other than the correction to that date, the remainder of the Original Form 8-K remains unchanged.
Entity Emerging Growth Company false
Document Period End Date Jun. 06, 2024
Entity File Number 000-30415
Entity Incorporation State Country Code NV
Entity Tax Identification Number 87-0699977
Entity Address Address Line 1 21 East Long Lake Road
Entity Address Address Line 2 Suite 100
Entity Address City Or Town Bloomfield Hills
Entity Address State Or Province MI
Entity Address Postal Zip Code 48304
City Area Code 248
Local Phone Number 452-9866
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ZIVO
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false

Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Zivo Bioscience Charts.
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Zivo Bioscience Charts.